Focus: Takeda is a Tokyo-based multinational pharmaceutical company with 49,000 employees specializing in small molecules and enzymes across gastroenterology, rare diseases, neuroscience, and oncology. It is one of the world's largest pharmaceutical companies by headcount and revenue scale.
Profile data last refreshed 16h ago · AI intelligence enriched 1mo ago
Hot — 1355 jobs added in 30d
Net +680 (1355 new, 675 removed). Aggressive expansion phase.
5 recent layoff filings (12 mo) — 637 affected
Source: state DOL filings via Big Local News
Takeda offers a stable Big Pharma foundation with strong current franchises and global reach, but the looming patent cliff (2028–2029) combined with recent layoffs signal near-term restructuring risk; best suited for candidates seeking established-market expertise rather than long-term growth trajectory.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Takeda's largest single revenue contributor (26% of revenue), providing a stable cash stream until patent expiry in 2032.
Help build intelligence for Takeda
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Takeda's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second-largest revenue driver; faces patent cliff in 2029, exposing the company to significant revenue erosion in the medium term.
Established neuroscience franchise supporting revenue, though lifecycle stage and patent data indicate no defined expiration in dataset.
Oncology franchise with patent protection until 2033, contributing meaningfully to specialty pharma positioning.
Recent FDA expansion approval for intravenous formulation (June 2026) positions this GI franchise as a growth driver; 16.99M shares granted June 2026 suggest company confidence.
GI market mainstay with patent protection until 2032, contributing to Takeda's gastroenterology portfolio depth.
GI-focused product facing patent expiration in 2028, making it a near-term cliff risk requiring pipeline replacement.
Rare disease franchise supporting niche indication; lifecycle and patent data indicate no defined expiration in dataset.
43 discontinued, 19 duplicate formulations not shown
+16 more products with revenue data
Fierce Pharma Asia—Takeda’s historic narcolepsy nod; Daiichi’s accounting error; Astellas’ revenue beat - Fierce Pharma
Fierce Pharma Asia—Takeda’s historic narcolepsy nod; Daiichi’s accounting error; Astellas’ revenue beat Fierce Pharma
Takeda (TAK) insider Nicola Greenway plans sale of 34,603 ADSs - stocktitan.net
Takeda (TAK) insider Nicola Greenway plans sale of 34,603 ADSs stocktitan.net
Takeda approval ushers in new wave of sleep drugs - BioPharma Dive
Takeda approval ushers in new wave of sleep drugs BioPharma Dive
Takeda wins U.S. FDA approval for narcolepsy drug ORZEYFUL - International Business Times
Takeda wins U.S. FDA approval for narcolepsy drug ORZEYFUL International Business Times
Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval - Benzinga
Takeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval Benzinga
Takeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful - Fierce Pharma
Takeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful Fierce Pharma
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Analysis of healthcare resource utilization before and after initiation of maribavir for cytomegalovirus treatment.
Bleeding rates, healthcare utilization, and costs among patients with hemophilia a without inhibitors treated with concomitant octocog alfa or extended half-life factor VIII while on emicizumab prophylaxis.
+4 more products
+2 more
+2 more
+2 more
+1 more
+2 more
Source: state DOL filings, aggregated via Big Local News
Cambridge-based R&D roles face significant attrition risk; restructuring appears tied to pipeline deprioritization ahead of patent cliffs; candidates should clarify program viability and site stability during interviews.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo